Okyo Pharma Share Discussion Threads

[zen12] 01/8/2018 07:46

RNS - Reads very much like their prospectus a few weeks ago. This extract is interesting though as it appears their off the ground with the Chemerin project: Since the first quarter of 2018, the Company had been engaged in re-listing activity which was became effective on 17 July 2018. At the same time, the Company remained focused on setting up life science operations in order to seek to develop the Chemerin Project.’

[bckttsim] 31/7/2018 21:06

Why do people have to copy the RNSPerhaps they think people are stupid and will not see it ?

[euclid5] 31/7/2018 20:49

"Early stage of operations

The Company's operations are at an early stage of development and there can be no guarantee that the Company will be able to, or that it will be commercially advantageous for the Company to, develop its proprietary technology and acquire scientific assets. Further, the Company has no positive operating cash flow and its ultimate success will depend on the Board's' ability to implement the Company's strategy, generate cash flow and access equity markets. Whilst the Board is optimistic about the Company's prospects, there is no certainty that anticipated outcomes and sustainable revenue streams will be achieved.

The Company will not generate any material income until commercialisation or licensing of its scientific assets has successfully commenced and in the meantime the Company will continue to expend its cash reserves. There can be no assurance that the Company's proposed operations will be profitable or produce a reasonable return, if any, on investment"

Technology and products

The Company is a drug discovery and development Company. The development and commercialisation of its scientific assets, will require research progress and positive results from multiple clinical trials, which by their very nature are inherently uncertain.

There is a risk that safety issues may arise when the products are tested. This risk is common to all new classes of drugs and, as with all other drug companies, there is a risk that trials may not be successful. The Board takes steps to ensure that all research partners adhere to industry standard guidelines.

Research and development risk

The Company operates in the life sciences and biopharmaceutical development sector and will be looking to exploit opportunities within that sector. The Company is therefore involved in complex scientific research, and industry experience indicates that there may be a very high incidence of delay or failure to produce results. The Company may not be able to develop new products or to identify specific market needs that can be addressed by technology solutions developed by the Company.

The ability of the Company to develop new technology relies, in part, on the recruitment of appropriately qualified staff as the Company grows, or to identify and collaborate with high quality scientific teams and investigators. The Company may be unable to find a sufficient number of appropriately highly trained individuals to satisfy its growth rate which could affect its ability to develop as planned.

Product development timelines

Product development timelines are at risk of delay, particularly since it is not always possible to predict the rate of patient recruitment into clinical trials. There is a risk therefore that product development could take longer than presently expected; if such delays occur the Company may require further working capital. The Company will seek to minimise the risk of delays by careful management of projects.

Uncertainty related to regulatory approvals

The Company will need to obtain various regulatory approvals and otherwise comply with extensive regulations regarding safety, quality and efficacy standards in order to market its future products. These regulations, including the time required for regulatory review, vary from country to country and can be lengthy, expensive and uncertain. While efforts will be made to ensure compliance with government standards, there is no guarantee that any products will be able to achieve the necessary regulatory approvals to promote that product in any of the targeted markets and any such regulatory approval may include significant restrictions for which the Company's products can be used.

In addition, the Company may be required to incur significant costs in obtaining or maintaining its regulatory approvals. Delays or failure in obtaining regulatory approval for products would be likely to have a serious adverse effect on the value of the Company and have a consequent impact on its financial performance and ability to continue as a going concern without raising additional finance. The Board takes steps to mitigate this risk by the appointment of regulatory specialists prior to any regulatory applications.

Future funding requirements

The Company will need to raise additional funding in the future to undertake work beyond that being funded by the Company's current cash reserves. There is no certainty that this will be possible at all or on acceptable terms. In addition, the terms of any such financing may be dilutive to, or otherwise adversely affect, existing shareholders.

[reks] 31/7/2018 12:34

Looks like news incoming regarding licenses

[the big fella] 31/7/2018 11:56

THE BIG FELLA19 Jul '18 - 16:18 - 14 of 140
0 1 0
I only needed to check who the corporate advisor was to know to give this a wide berth. Good old Beaumont Crusty. What do you get here for near 30 mil mkt cap? I suspect an empty wallet.

Some will only learn the hard way.

[stenick] 27/7/2018 18:32

More like Chico time as.

[stenick] 27/7/2018 15:08

andrbea can u post a bit more info on your thread about what OKYO has and intends doing as I think this bird needs direction.

[stenick] 26/7/2018 16:12

I know it’s hot out but you got to flap harder.

[welshshark] 26/7/2018 16:02

What time is it??it Okyo time

[stenick] 26/7/2018 14:07

Come on start flapping them wings.

[welshshark] 26/7/2018 13:27

Whatch it fly later today and tomorrow,like this businesses huge reward coming,they didn’t reverse for main market status for nothing.

[a1samu] 26/7/2018 08:34

All hope at the moment for the miner turned pharma company.

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc.

OKYO Pharma’s future strategy is to differentiate itself by focusing on opportunities where clinical development timelines are short. It is the intention that OKYO Pharma will work closely with its retained clinicians with a view to generating incremental value for its shareholders.

[a1samu] 26/7/2018 08:30

Directors of the company, run by a gambler
Executive Director

Willy Simon
Willy Simon
Willy Jules Simon is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. From 2004 until 2012, Mr. Simon served as a non-executive director of Redi & Partners Ltd., a fund of funds. He was previously chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2015 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company. He is also a non-executive director of Tiziana Life Sciences plc.


Non-Executive Directors

Kunwar Shailubhai
Dr. Kunwar Shailubhai M.B.A., Non-Executive Director
Kunwar Shailubhai, Ph.D., M.B.A. serves as chief executive officer, chief scientific officer and executive director of Tiziana Life Sciences plc. Dr. Shailubhai brings more than 25 years of experience within the life science industry, combined with a distinguished track record of success in translating drugs from concept through commercialisation to market. He also currently serves as chief executive officer of Rasna Therapeutics, Inc., a developer of therapeutics to address the high unmet need that exists for acute myeloid leukaemia and other forms of leukaemia.

Dr. Shailubhai has been serving as a member of board of Tiziana Life Sciences plc since 2015. He actively played key roles in development of growth strategies through several key licensings of technologies and drug candidates. Dr. Shailubhai steered Tiziana Life Sciences plc through prioritisation of projects to focus on novel drug candidates for treatment of autoimmune and inflammatory diseases and cancer.

As co-founder, executive vice-president and chief scientific officer of Synergy Pharmaceuticals, Inc. he led the non-clinical, chemistry, manufacture, controls and clinical development of TrulanceTM from inception to approval by the FDA, having co-invented and pioneered Synergy’s platform technology for functional gastrointestinal disorders, inflammatory bowel disease, gastrointestinal cancer and other human diseases. Dr. Shailubhai, as the chief architect of the intellectual property estate, directed all aspects of intellectual property management, including timely submission of patent applications, directing office actions and coordinating with intellectual property attorneys. Earlier, from 2003 until 2008, Dr. Shailubhai served as senior vice president, Drug Discovery and from 2001 to 2003, he held the position of vice president, Drug Discovery at Synergy, where he pioneered therapeutic applications of Guanylate Cyclease-C agonists in a variety of human diseases such as Asthma, Chronic Obstructive Pulmonary Disease and cholesterol lowering. Prior to Synergy, he was with Monsanto Company, serving as group leader, Cancer Prevention and previously served as a senior staff fellow at the National Institutes of Health, and as an assistant professor at the University of Maryland. Dr. Shailubhai received his Ph.D. in microbiology from the University of Baroda, India, and his M.B.A. from the University of Missouri, St. Louis. He has more than 20 issued patents and over 50 peer-reviewed publications.

Leopolodo Zambeletti
Leopoldo Zambeletti
Mr. Zambeletti is an independent strategic advisor in the Healthcare sector. He started his career at KPMG as an auditor followed by a successful career as an investment banker, having led the European and MENA Healthcare Investment Banking teams at JP Morgan and Credit Suisse for a combined total of 19 years. As an independent advisor, he advises life science companies on merger and acquisitions, out-licensing deals and financing strategy.

He is a non-executive director of, Qardio Inc., Summit Therapeutics plc, Nogra Pharma Limited, Faron Pharmaceuticals OY, DS Biopharma Limited, Afimmune Ltd. and Overjoy Srl. Until recently he served as advisor and Board member to Advanced Accelerator Applications and trustee to Barts and the London Charity. He is the founder of the cultural initiative 5x5 Italy. He is also a non-executive director of Tiziana Life Sciences plc.

Mr. Zambeletti received a B.A. in Business from Bocconi University in Milan, Italy.

Senior Management
Tiziano Lazzaretti
Tiziano Lazzaretti, Chief Financial Officer
Mr. Lazzaretti acts as OKYO Pharma’s chief financial officer. Mr. Lazzaretti has extensive experience in the healthcare and pharmaceutical industry and is chief financial officer of Tiziana Life Sciences plc and Rasna Therapeutics, Inc., from 2011 to 2016 he was group finance director at Pharmentis Srl, a spin-off from Teva Ratiopharm. Prior to this, Mr. Lazzaretti was an executive director at Alliance Boots Healthcare, and held senior positions at Accenture, SNIA Spa and Fiat Group. Mr. Lazzaretti has a Bachelor of Science (BSc Hons) in Accounting and Finance from the University of Turin, Italy, was awarded a M.B.A. from Bocconi University, Milan and studied Corporate Finance at the London Business School.

[welshshark] 26/7/2018 07:55

Just remember guys this is not aim,but main market listing,this will be much bigger and higher share price in the coming days imo.

[stenick] 25/7/2018 17:34

I’m someone who does my reasearch.

[stenick] 25/7/2018 17:08

Wow you know something then?

[welshshark] 25/7/2018 16:12

Can someone tell ch on lse stop ramping,no need to ramp this up as it has fantastic bod and life changing product,just matter of time before £300m+ deal is done,just sit back and enjoy the ride.

[alexios1201] 25/7/2018 13:41

kingstonRelisted on the main market with change of name and pharma play

[olly1972] 25/7/2018 12:44

Moving on up again.

[seagreen] 24/7/2018 12:31

lazy muppet ...dyor

[kingston78] 24/7/2018 09:34

Isn't this share delisted from AIM? How can people trade it?

[dave4545] 24/7/2018 08:11

The lure of a fast buck combined taking on mm's with a low nms means people who buy too much and then try to sell it when the mm's do not want it resulting in big losses.

Weird these days, there is unlimited value out there on Aim but because they are not shooting up nobody wants to play them all

[a1samu] 24/7/2018 08:08

Where is the value? This is all hope with no pedigree.

[zen12] 23/7/2018 17:09

Unfortunately not this time.